| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
Departments of 1 Pharmacology and 2 Biostatistics, University of Pittsburgh and 3 The University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Requests for reprints: Mark Nichols, Hillman Cancer Center, Suite 2.26a, 5117 Center Avenue, Pittsburgh, PA 15213-1863. Phone: 412-623-7782; Fax: 412-623-4840; E-mail: mnichols{at}pitt.edu.
Estrogen receptor (ER) agonists and antagonists elicit distinct responses in nonsmall cell lung cancer (NSCLC) cells. To determine how such responses are generated, the expression of ER
, ERß, and ER coregulators in human lung fibroblasts and human NSCLC cell lines was evaluated by immunoblot. Ligand-dependent estrogenic responses in NSCLC cells are probably generated via ERß and the p160 coactivator GRIP1/TIF2, because expression of these proteins was detected, but not full-length ER
or the p160 coactivator SRC-1. ERß and GRIP1/TIF2 are shown to interact in vitro in a ligand-dependent manner and thus may form functional transcription complexes in NSCLC cells. Furthermore, the capacity of ER ligands to regulate gene expression in NSCLC cells was explored using gene miniarrays. Expression profiles were examined after treatment with ER agonist 17-ß-estradiol (E2), the pure ER antagonist ICI 182,780 (fulvestrant, Faslodex), or epidermal growth factor, which served as a positive control for an alternative growth stimulus. E-cadherin and inhibitor of differentiation 2 were differentially regulated by E2 versus ICI 182,780 in 201T and 273T NSCLC cell lines. Epidermal growth factor also stimulated proliferation of these cells but had no effect on expression of E-cadherin and inhibitor of differentiation 2, suggesting they are specific targets of ER signaling. These data show that NSCLC cells respond to estrogens/antiestrogens by altering endogenous gene expression and support a model in which ICI 182,780 reduces proliferation of NSCLC cells via its ability to disrupt ER signaling. ICI 182,780 may therefore have therapeutic benefit in NSCLC.
Key Words: Estradiol ICI 182,780 Estrogen Receptor nonsmall cell lung cancer TIF2
This article has been cited by other articles:
![]() |
E. M. Bahassi, S. B. Robbins, M. Yin, G. P. Boivin, R. Kuiper, H. van Steeg, and P. J. Stambrook Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias PNAS, October 6, 2009; 106(40): 17111 - 17116. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Raso, C. Behrens, M. H. Herynk, S. Liu, L. Prudkin, N. C. Ozburn, D. M. Woods, X. Tang, R. J. Mehran, C. Moran, et al. Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation Clin. Cancer Res., September 1, 2009; 15(17): 5359 - 5368. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, X. Liu, A. M. Farkas, A. V. Parwani, K. L. Lathrop, D. Lenzner, S. R. Land, and H. Srinivas Estrogen Receptor {beta} Functions through Nongenomic Mechanisms in Lung Cancer Cells Mol. Endocrinol., February 1, 2009; 23(2): 146 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, et al. Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors Cancer Res., February 1, 2009; 69(3): 914 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Niikawa, T. Suzuki, Y. Miki, S. Suzuki, S. Nagasaki, J. Akahira, S. Honma, D. B. Evans, S.-i. Hayashi, T. Kondo, et al. Intratumoral Estrogens and Estrogen Receptors in Human Non-Small Cell Lung Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4417 - 4426. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Hammoud, B. Tan, S. Badve, and R. M Bigsby Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma Endocr. Relat. Cancer, June 1, 2008; 15(2): 475 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Schwartz, A. S. Wenzlaff, G. M. Prysak, V. Murphy, M. L. Cote, S. C. Brooks, D. F. Skafar, and F. Lonardo Reproductive Factors, Hormone Use, Estrogen Receptor Expression and Risk of Non Small-Cell Lung Cancer in Women J. Clin. Oncol., December 20, 2007; 25(36): 5785 - 5792. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Mah, D. B. Seligson, A. Li, D. C. Marquez, I. I. Wistuba, Y. Elshimali, M. C. Fishbein, D. Chia, R. J. Pietras, and L. Goodglick Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer Cancer Res., November 1, 2007; 67(21): 10484 - 10490. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tsuchiya, M. Iwasaki, T. Otani, J.-i. Nitadori, K. Goto, Y. Nishiwaki, Y. Uchitomi, and S. Tsugane Breast Cancer in First-degree Relatives and Risk of Lung Cancer: Assessment of the Existence of Gene-Sex Interactions Jpn. J. Clin. Oncol., June 23, 2007; (2007) hym048v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Subramanian and R. Govindan Lung Cancer in Never Smokers: A Review J. Clin. Oncol., February 10, 2007; 25(5): 561 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Johnson The SERM of My Dreams. J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3754 - 3756. [Full Text] [PDF] |
||||
![]() |
B. R. Vuillemenot, J. A. Hutt, and S. A. Belinsky Gene Promoter Hypermethylation in Mouse Lung Tumors Mol. Cancer Res., April 1, 2006; 4(4): 267 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Siegfried Hormone Replacement Therapy and Decreased Lung Cancer Survival J. Clin. Oncol., January 1, 2006; 24(1): 9 - 10. [Full Text] [PDF] |
||||
![]() |
A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, and S. Brooks Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex Clin. Cancer Res., October 15, 2005; 11(20): 7280 - 7287. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |